Cargando…

Long-term Testis Cancer Survivors in Canada—Mortality Risks in a Large Population-based Cohort

BACKGROUND: Testis cancer (TC) patients are young with excellent cancer prognosis. Hence, the risk of late-onset treatment-related morbidity and mortality is of concern due to longer survival after treatment. OBJECTIVE: We set to characterize long-term survival of TC patients through a Canadian popu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavi, Arnon, Clark, Roderick, Ly, Tina Luu, Nair, Shiva M., Hetou, Khalil, Haan, Michael, Power, Nicholas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317812/
https://www.ncbi.nlm.nih.gov/pubmed/34337478
http://dx.doi.org/10.1016/j.euros.2020.10.005
_version_ 1783730125693517824
author Lavi, Arnon
Clark, Roderick
Ly, Tina Luu
Nair, Shiva M.
Hetou, Khalil
Haan, Michael
Power, Nicholas E.
author_facet Lavi, Arnon
Clark, Roderick
Ly, Tina Luu
Nair, Shiva M.
Hetou, Khalil
Haan, Michael
Power, Nicholas E.
author_sort Lavi, Arnon
collection PubMed
description BACKGROUND: Testis cancer (TC) patients are young with excellent cancer prognosis. Hence, the risk of late-onset treatment-related morbidity and mortality is of concern due to longer survival after treatment. OBJECTIVE: We set to characterize long-term survival of TC patients through a Canadian population dataset. DESIGN, SETTING, AND PARTICIPANTS: We used a population-based dataset, the Canadian Census Health and Environment Cohort (CanCHEC), to identify individuals diagnosed with TC between 1991 and 2010. We compared them with all other male individuals without TC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was mortality due to cardiovascular disease (CVD) or nontesticular malignancy. Mann-Whitney or chi-square test was used where applicable. Data were analyzed using a Cox proportional hazard model with and without matching. RESULTS AND LIMITATIONS: We identified 1950 individuals with TC. We compared them with 1 300 295 men with no TC. There were 335 deaths in the study group during the study period (17.2%) with a mean follow-up of 19.6 yr. TC patients were at increased risk of death from secondary malignancies (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.39–1.91; p < 0.0001) with specific risks for hematologic neoplasms (HR 3.86, 95% CI 2.78–5.37; p < 0.001) and other malignancies (HR 2.41, 95% CI 1.76–3.29; p < 0.001). Gastrointestinal, hematologic, and respiratory toxicities were the most common secondary malignancies leading to death. When stratified according to histology, nonseminoma (NS) patients were at significantly increased risk of death from CVD (HR 2.03, 95% CI 1.27–3.25; p = 0.0032). Individuals with seminoma were at increased risk of death from other nontestis neoplasms (HR 1.46, 95% CI 1.17–1.82; p = 0.0007), specifically hematologic neoplasms (HR 2.09, 95% CI 1.18–3.72; p = 0.0118). CONCLUSIONS: NS patients are at increased risk of CVD-related death, whereas seminoma patients are at increased risk of death from non–testis-related malignancies. PATIENT SUMMARY: We report long-term mortality following diagnosis of testis cancer. Nonseminoma patients have an increased risk of death from cardiovascular disease, while seminoma patients have an increased risk of death from secondary malignancies.
format Online
Article
Text
id pubmed-8317812
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83178122021-07-29 Long-term Testis Cancer Survivors in Canada—Mortality Risks in a Large Population-based Cohort Lavi, Arnon Clark, Roderick Ly, Tina Luu Nair, Shiva M. Hetou, Khalil Haan, Michael Power, Nicholas E. Eur Urol Open Sci Testis Cancer BACKGROUND: Testis cancer (TC) patients are young with excellent cancer prognosis. Hence, the risk of late-onset treatment-related morbidity and mortality is of concern due to longer survival after treatment. OBJECTIVE: We set to characterize long-term survival of TC patients through a Canadian population dataset. DESIGN, SETTING, AND PARTICIPANTS: We used a population-based dataset, the Canadian Census Health and Environment Cohort (CanCHEC), to identify individuals diagnosed with TC between 1991 and 2010. We compared them with all other male individuals without TC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was mortality due to cardiovascular disease (CVD) or nontesticular malignancy. Mann-Whitney or chi-square test was used where applicable. Data were analyzed using a Cox proportional hazard model with and without matching. RESULTS AND LIMITATIONS: We identified 1950 individuals with TC. We compared them with 1 300 295 men with no TC. There were 335 deaths in the study group during the study period (17.2%) with a mean follow-up of 19.6 yr. TC patients were at increased risk of death from secondary malignancies (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.39–1.91; p < 0.0001) with specific risks for hematologic neoplasms (HR 3.86, 95% CI 2.78–5.37; p < 0.001) and other malignancies (HR 2.41, 95% CI 1.76–3.29; p < 0.001). Gastrointestinal, hematologic, and respiratory toxicities were the most common secondary malignancies leading to death. When stratified according to histology, nonseminoma (NS) patients were at significantly increased risk of death from CVD (HR 2.03, 95% CI 1.27–3.25; p = 0.0032). Individuals with seminoma were at increased risk of death from other nontestis neoplasms (HR 1.46, 95% CI 1.17–1.82; p = 0.0007), specifically hematologic neoplasms (HR 2.09, 95% CI 1.18–3.72; p = 0.0118). CONCLUSIONS: NS patients are at increased risk of CVD-related death, whereas seminoma patients are at increased risk of death from non–testis-related malignancies. PATIENT SUMMARY: We report long-term mortality following diagnosis of testis cancer. Nonseminoma patients have an increased risk of death from cardiovascular disease, while seminoma patients have an increased risk of death from secondary malignancies. Elsevier 2020-11-20 /pmc/articles/PMC8317812/ /pubmed/34337478 http://dx.doi.org/10.1016/j.euros.2020.10.005 Text en Crown Copyright © 2020 Published by Elsevier B.V. on behalf of European Association of Urology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Testis Cancer
Lavi, Arnon
Clark, Roderick
Ly, Tina Luu
Nair, Shiva M.
Hetou, Khalil
Haan, Michael
Power, Nicholas E.
Long-term Testis Cancer Survivors in Canada—Mortality Risks in a Large Population-based Cohort
title Long-term Testis Cancer Survivors in Canada—Mortality Risks in a Large Population-based Cohort
title_full Long-term Testis Cancer Survivors in Canada—Mortality Risks in a Large Population-based Cohort
title_fullStr Long-term Testis Cancer Survivors in Canada—Mortality Risks in a Large Population-based Cohort
title_full_unstemmed Long-term Testis Cancer Survivors in Canada—Mortality Risks in a Large Population-based Cohort
title_short Long-term Testis Cancer Survivors in Canada—Mortality Risks in a Large Population-based Cohort
title_sort long-term testis cancer survivors in canada—mortality risks in a large population-based cohort
topic Testis Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317812/
https://www.ncbi.nlm.nih.gov/pubmed/34337478
http://dx.doi.org/10.1016/j.euros.2020.10.005
work_keys_str_mv AT laviarnon longtermtestiscancersurvivorsincanadamortalityrisksinalargepopulationbasedcohort
AT clarkroderick longtermtestiscancersurvivorsincanadamortalityrisksinalargepopulationbasedcohort
AT lytinaluu longtermtestiscancersurvivorsincanadamortalityrisksinalargepopulationbasedcohort
AT nairshivam longtermtestiscancersurvivorsincanadamortalityrisksinalargepopulationbasedcohort
AT hetoukhalil longtermtestiscancersurvivorsincanadamortalityrisksinalargepopulationbasedcohort
AT haanmichael longtermtestiscancersurvivorsincanadamortalityrisksinalargepopulationbasedcohort
AT powernicholase longtermtestiscancersurvivorsincanadamortalityrisksinalargepopulationbasedcohort